Acorda Therapeutics, Inc. (ACOR) financial statements (2022 and earlier)

Company profile

Business Address 420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4671126446307159
Cash and cash equivalents467162294307159
Short-term investments  64152  
Restricted cash and investments131313100
Receivables172022238152
Inventory, net of allowances, customer advances and progress billings19292529  
Inventory19292529  
Prepaid expense71512191313
Assets held-for-sale, not part of disposal group 72    
Other current assets1241026
Other undisclosed current assets    3843
Total current assets:102221201528442273
Noncurrent Assets
Operating lease, right-of-use asset71823
Property, plant and equipment47143613734
Intangible assets, net (including goodwill)3363674027117171,023
Goodwill   282287281
Intangible assets, net (excluding goodwill)336367402429431742
Restricted cash and investments61930   
Deferred costs    22
Other noncurrent assets000016
Other undisclosed noncurrent assets     4
Total noncurrent assets:3534115997727561,070
TOTAL ASSETS:4556338001,3001,1981,342
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities395065126127132
Accounts payable111226492727
Accrued liabilities29383977100105
Debt 698117
Business combination, contingent consideration, liability2225  
Deferred revenue and credits99
Other undisclosed current liabilities13171197 
Total current liabilities:5413786140144148
Noncurrent Liabilities
Long-term debt and lease obligation183183241343334324
Long-term debt, excluding current maturities179166218343334324
Operating lease, liability41723
Liabilities, other than long-term debt6868155183155120
Deferred revenue and credits2332
Deferred income tax liabilities141910
Liability for uncertainty in income taxes  7877
Other liabilities61012129
Business combination, contingent consideration, liability48477816311372
Derivative instruments and hedges, liabilities0159   
Other undisclosed noncurrent liabilities 76224486
Total noncurrent liabilities:250257403547534530
Total liabilities:304395489688678678
Stockholders' equity
Stockholders' equity attributable to parent151238311612520664
Common stock000000
Treasury stock, value(1)(1)(1)(2)(0)(0)
Additional paid in capital1,0231,0089791,005969921
Accumulated other comprehensive income (loss)(1)(3)(1)37(13)
Accumulated deficit(870)(766)(667)(394)(455)(244)
Total stockholders' equity:151238311612520664
TOTAL LIABILITIES AND EQUITY:4556338001,3001,1981,342

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues129153192471588520
Revenue, net588520
Cost of revenue(64)(41)(35)(144)(162)(117)
Cost of goods and services sold(41)(34)(35)(99)(135)(107)
Gross profit:65112158327427403
Operating expenses(144)(190)(530)(289)(660)(439)
Other undisclosed operating income  61   
Operating income (loss):(79)(78)(312)38(233)(36)
Nonoperating income (expense)(30)(30)37(18)(19)(6)
Investment income, nonoperating014400
Other nonoperating income (expense)(0)000(1)10
Interest and debt expense555555(22)(19)(17)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes (55)(55)221917
Income (loss) from continuing operations before equity method investments, income taxes:(54)(108)(274)20(252)(42)
Other undisclosed income (loss) from continuing operations before income taxes(55)  0  
Income (loss) from continuing operations before income taxes:(109)(108)(274)20(252)(42)
Income tax benefit58113297
Net income (loss):(104)(100)(273)34(223)(36)
Net income attributable to noncontrolling interest     1
Net income (loss) available to common stockholders, basic:(104)(100)(273)34(223)(35)
Interest on convertible debt126    
Net income (loss) available to common stockholders, diluted:(92)(93)(273)34(223)(35)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):(104)(100)(273)34(223)(36)
Other comprehensive income (loss)2(2)(4)(4)20(13)
Comprehensive income (loss):(102)(101)(277)30(204)(48)
Comprehensive income, net of tax, attributable to noncontrolling interest     0
Comprehensive income (loss), net of tax, attributable to parent:(102)(101)(277)30(204)(48)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: